International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its ...

AstraZeneca presented data from the phase 3 BATURA study which showed that use of Airsupra in those with mild asthma reduced ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

Tozorakimab: Demonstrating potential benefits of tozorakimab to reduce excess inflammation in IL-33 driven diseases • FRONTIER phase II programme: results from four studies across asthma and COPD ...

Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.

Credit: crystal light/Shutterstock. On 18 May at the 2025 American Thoracic Society (ATS) International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, ...

Bermekimab (IL-1α neutralization), PF-06650833 (IRAK4 inhibitor blocking downstream signaling), Tadekinig alfa (Th17 balance modulation via IL-18BP), Astegolimab and Tozorakimab (targeting IL-33 ...